Quarterly UpdatesJul 15, 2026, 07:01 AM
Pediatrix Reaffirms 2026 Adj. EBITDA Outlook $280M-$300M; Stable Q2 Payor Mix
AI Summary
Pediatrix Medical Group provided an update on its second quarter 2026 business trends, confirming that its payor mix remained stable and unchanged, unlike shifts reported by other healthcare market participants. The company has not experienced unfavorable payor mix shifts or material changes in net revenue-related trends. Pediatrix reaffirmed its full-year 2026 Adjusted EBITDA outlook in the range of $280 million to $300 million. The company will host an investor conference call on August 4, 2026, to discuss its full Q2 results.
Key Highlights
- Reaffirmed full-year 2026 Adjusted EBITDA outlook of $280 million to $300 million.
- Second quarter payor mix remained stable and unchanged.
- Did not experience unfavorable payor mix shifts reported by other healthcare participants.
- No material changes in other net revenue-related trends.
- Q2 2026 earnings conference call scheduled for August 4, 2026.
Price Impact
More from MD